Article
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.
Nature communications - 8 Dec 2016
Van Emburgh Beth O, Arena Sabrina, Siravegna Giulia, Lazzari Luca, Crisafulli Giovanni, Corti Giorgio, Mussolin Benedetta, Baldi Federica, Buscarino Michela, Bartolini Alice, Valtorta Emanuele, Vidal Joana, Bellosillo Beatriz, Germano Giovanni, Pietrantonio Filippo, Ponzetti Agostino, Albanell Joan, Siena Salvatore, Sartore-Bianchi Andrea, Di Nicolantonio Federica, Montagut Clara, Bardelli Alberto
Abstract excerpt
Blockade of the epidermal growth factor receptor (EGFR) with the monoclonal antibodies cetuximab or panitumumab is effective in a subset of colorectal cancers (CRCs), but the emergence of resistance limits the efficacy of these therapeutic agents. At relapse, the majority of patients develop RAS mutations, while a subset acquires EGFR extracellular domain (ECD) mutations. Here we find that patients who experience...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.